CYP2A13, ADH1B, and ADH1C Gene Polymorphisms and Pancreatic Cancer Risk

Objectives: Pancreatic carcinoma etiology and molecular pathogenesis are weakly understood. Based on the assumption that genetic variation in carcinogen metabolism further modifies the risk of exposure-related cancers, we studied the association of polymorphisms in the tobacco carcinogen-metabolizing gene CYP2A13 (Arg101Stop) and the alcohol-metabolizing genes ADH1B (Arg48His) and ADH1C (Ile350Val) with pancreatic cancer risk. Methods: Polymorphisms were studied by allelic discrimination. Results: In a hospital-based case-control study, CYP2A13 variant alleles coding an inactive enzyme were found in 7 of 265 cancer-free controls and in none of 235 pancreatic carcinoma patients. Neither ADH1B or ADH1C polymorphisms alone nor their combinations showed a significant effect on pancreatic cancer risk. Conclusions: The first study of the roles of CYP2A13, ADH1B, and ADH1C in pancreatic cancer etiology suggested that the controls may have a lower ability to bioactivate tobacco-derived procarcinogens than the cases.